May 10, 2019 / 7:39 PM / 15 days ago

BRIEF-Vifor Pharma'S Phase-II Amber Study Meets Primary Endpoint

May 10 (Reuters) - Vifor Pharma AG:

* VIFOR PHARMA’S PHASE-II AMBER STUDY MEETS PRIMARY ENDPOINT

* VIFOR PHARMA AG - VELTASSA WAS SHOWN TO ENABLE PERSISTENT USE OF SPIRONOLACTONE BY CONTROLLING BLOOD POTASSIUM LEVELS

* VIFOR PHARMA AG - SAFETY RESULTS FROM STUDY ARE CONSISTENT WITH EXISTING VELTASSA DATA, WITH NO NEW SAFETY ISSUES IDENTIFIED.

* VIFOR PHARMA AG - CHALLENGING FOR MANY PATIENTS TO STAY ON SPIRONOLACTONE TREATMENT BECAUSE IT CAN FURTHER INCREASE RISK OF HYPERKALAEMIA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below